References
- WHO. Obesity: data and statistics. [cited 2017 Nov 17]. Available from: http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-and-statistics.
- Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42:563–570.
- Ogden CL, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS Data Brief. 2015:1–8. [cited 2017 Nov 17]. Available from: https://www.cdc.gov/nchs/data/databriefs/db219.pdf.
- Hunt A, Ferguson J. Health costs in the European Union: how much is related to EDCS? Brussels:The Health and Environmental Alliance. 2014. [cited 2017 Nov 17]. Available from: http://www.env-health.org/IMG/pdf/18062014_final_health_costs_in_the_european_union_how_much_is_realted_to_edcs.pdf.
- Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28:w822–31.
- Rudisill C, Charlton J, Booth HP, et al. Are healthcare costs from obesity associated with body mass index, comorbidity or depression? Cohort study using electronic health records. Clin Obes. 2016;6:225–231.
- Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121:21–33.
- Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing diabetes prevention study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474–480.
- Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36:641–649.
- Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
- Curioni CC, Lourenco PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond). 2005;29:1168–1174.
- Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg. 2014;24:42–55.
- Jensen MD, Ryan DH, Apovian CM, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. Circulation. 2013;2014(129):S102–S138.
- Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1–203.
- Dr F, Sh B, Wc K, et al.; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445–454.
- Westerveld D, Yang D. Through thick and thin: identifying barriers to bariatric surgery, weight loss maintenance, and tailoring obesity treatment for the future. Surg Res Pract. 2016;2016:8616581.
- Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. Jama. 2014;311:74–86.
- Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13:491–500.
- Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33:1299–1307.
- Thomas CE, Mauer EA, Shukla AP, et al. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity. 2016;24:1955–1961.
- Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine–phentermine. New Engl J Med. 1997;337:581–588.
- James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. New Engl J Med. 2010;36:905–917.
- Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706–1713.
- Patel D. Pharmacotherapy for the management of obesity. Metabolism. 2015;64:1376–1385.
- Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–161.
- Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–1352.
- Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–342.
- Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.
- Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21:2163–2171.
- VIVUS reports topline findings from FORTRESS. Mountain View, CA: VIVUS Inc; 2011 cited 2017 Nov 17. http://ir.vivus.com/releasedetail.cfm?ReleaseID=634920.
- Winslow DH, Bowden CH, DiDonato KP, et al. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35:1529–1539.
- Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
- Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–3077.
- O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20:1426–1436.
- Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
- Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–943.
- Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110–120.
- Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–4029.
- Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. Jama. 2016;315:990–1004.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
- Le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399–1409.
- Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. Jama. 2015;314:687–699.
- Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37:1443–1451.
- Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond). 2016;40:1310–1319.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
- EMA. Assessment report for orlistat-containing medicinal products, 2012. [2017 Nov 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Orlistat_31/WC500136703.pdf.
- Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013;4:171–181.
- XENICAL (orlistat) capsules for oral use prescribing information. South San Francisco, CA: Genetech USA, Inc.; 2016 2017 Nov 17. https://www.gene.com/download/pdf/xenical_prescribing.pdf.
- Garcia SB, Barros LT, Turatti A, et al. The anti-obesity agent orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2006;240:221–224.
- XENICAL (orlistat) preclinical and clinical summary report on colon cancer. 2006. [cited 2017 Nov 17]. Available from: https://www.fda.gov/ohrms/dockets/dockets/06p0154/06p-0154-c000002-04-Attachment-02-vol3.pdf.
- Hong JL, Meier CR, Sandler RS, et al. Risk of colorectal cancer after initiation of orlistat: matched cohort study. Bmj. 2013;347:f5039.
- Phentermine hydrochloride highlights of prescribing information. (ADIPEX-P®) FDA label. [cited 2017 Nov 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf.
- Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann N Y Acad Sci. 2014;1311:1–13.
- QSYMIA (phentermine and topiramate extended-release) Capsules Prescribing Information, VIVUS Inc: Mountain View, CA. 2014. [cited 2017 Nov 17]. Available from: https://www.qsymia.com/pdf/prescribing-information.pdf.
- Fujioka K. Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring). 2015;23(Suppl 1):S7–S11.
- QNEXA (phentermine/topiramate) Clinical Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2012. [cited 2017 Nov 17] https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292317.pdf.
- EMA. Assessment report, Qsiva, 2013. Available from: [cited 2017 Nov 17] http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002350/WC500144300.pdf.
- Wharton S, Serodio KJ. Next generation of weight management medications: implications for diabetes and CVD risk. Curr Cardiol Rep. 2015;17:35.
- Vivus operational announcement, March 2015. [cited 2017 Nov 17]. Available from: http://ir.vivus.com/releasedetail.cfm?ReleaseID=904060.
- Johnson B, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010;16:2103–2112.
- Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836–2841.
- Weissman NJ, Smith SR, Fain R, et al. Effects of lorcaserin on pre-existing valvulopathy: a pooled analysis of phase 3 trials. Obesity (Silver Spring). 2017;25:39–44.
- Eisai announces lorcaserin HCl CAMELLIA-TIMI 61 study will continue as planned based on interim safety analysis by independent data monitoring committee. Eisai Inc, 2017. [cited 2017 Nov 17]. Available from: http://eisai.mediaroom.com/2017-06-21-Eisai-Announces-Lorcaserin-HCl-CAMELLIA-TIMI-61-Study-will-Continue-as-Planned-Based-on-Interim-Safety-Analysis-by-Independent-Data-Monitoring-Committee-DMC.
- Belviq (lorcaserin hydrochloride) prescribing information, FDA. June 2012 [cited 2017 Nov 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf
- EMA. Questions and answers, withdrawal of the marketing authorisation application for Belviq (lorcaserin). May 30, 2013 [cited 2017 Nov 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2013/05/WC500143811.pdf
- Xr BELVIQ. (Lorcaserin hydrochloride) extended release 20 mg for oral use, medical review. Eisai Inc. Washington, DC: FDA; 2016. cited 2017 Nov 17. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208524s000lbl.pdf.
- Halpern B, Mancini MC. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert Opin Drug Saf. 2017;16:27–39.
- Contrave SMPC. London, UK: EMA. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003687/WC500185580.pdf [cited 2018 Jan 17]
- CONTRAVE (naltrexone HCl and bupropion HCl) extended release tablets prescribing information. Takeda Pharmaceuticals America, Inc. Washington, DC: FDA; 2014. cited 2017 Nov 17. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf.
- CONTRAVE (naltrexone HCl and bupropion HCl) extended relase tablets briefing document. Takeda Pharmaceuticals America, Inc. Washington, DC: FDA; 2010. cited 2017 Nov 17. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000MedR.pdf.
- Christou G, Katsiki N, Kiortis D. The current role of liraglutide in the pharmacotherapy of obesity. Curr Vasc Pharmacol. 2016;14:201–207.
- Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616.
- Smilowitz NR, Donnino R, Schwartzbard A. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. Circulation. 2014;129:2305–2312.
- Novo Nordisk A/S. CHMP endorses EU label update of Saxenda® based on the LEADER trial. June 27, 2017 [cited Nov 17]. Available from: https://globenewswire.com/news-release/2017/06/22/1027945/0/en/Novo-Nordisk-A-S-CHMP-endorses-EU-label-update-of-Saxenda-based-on-the-LEADER-trial.html.
- Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368:230–239.
- Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis – 2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–111.
- Steinberg WM, Rosenstock J, Wadden TA, et al. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care. 2017;40:839–848.
- Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012;153:1538–1547.
- SAXENDA (liraglutide [rDNA origin] injection) solution for subcutaneous use prescribing information. Novo Nordisk Inc. Washington, DC: FDA; 2014. [cited 2017 Nov 17. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf.
- Martin-Rodriguez E, Guillen-Grima F, Marti A, et al. Comorbidity associated with obesity in a large population: the APNA study. Obes Res Clin Pract. 2015;9:435–447.
- Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju SN, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388:776–786.
- Stender S, Nordestgaard BG, Tybjaerg-Hansen A. Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study. Hepatology. 2013;58:2133–2141.
- Johansson K, Sundstrom J, Marcus C, et al. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obes (Lond). 2014;38:279–284.
- Hong S, Qiwen B, Ying J, et al. Body mass index and the risk and prognosis of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:1136–1143.
- Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474–480.
- Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–1486.
- FDA. Guidance for Industry Developing Products for Weight Management [cited 2017 Nov 17]. Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf
- Cohen A, Goto S, Schreiber K et al. Why do we need observational studies of everyday patients in the real-life setting? Eur Heart J Suppl. 2015;17:D2–D8.
- Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond). 2009;33:289–295.
- The George Washington University. Obesity drug outcome measures: a consensus report of considerations regarding pharmacologic intervention. 2012 [cited 2017 Nov 17]. Available from: https://publichealth.gwu.edu/pdf/obesitydrugmeasures.pdf.